Can a Triple-Drug combo tackle breast cancer brain metastases?
NCT ID NCT07745257
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding anlotinib to a combination of culmerciclib and endocrine therapy can control disease in people with HR-positive, HER2-negative breast cancer that has spread to the brain. The study enrolls adults with newly diagnosed or progressing brain metastases who do not need immediate local treatment. The goal is to see if this drug combination can delay brain tumor growth and improve overall outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of three drugs: culmerciclib (a CDK inhibitor), anlotinib (an anti-angiogenic agent), and standard endocrine therapy.
- What this could lead to
- If successful, this combination could offer a new treatment option to control brain metastases in HR+/HER2- breast cancer, potentially improving outcomes for a group with limited options.
- What could go wrong
- This is a small, early-phase trial, so the benefits are uncertain. The drug combination may cause side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WITH BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anyang Tumor Hospital
Anyang, Henan, 455001, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
Nanchang People's Hospital
Nanchang, Jiangxi, 330009, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050011, China
-
The Second Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, 116021, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China